Zymo Drug Gets Canadian Approval

Xconomy Seattle — 

ZymoGenetics (NASDAQ: ZGEN), the Seattle-based biotech company, said today in a regulatory filing that its drug to control excess surgical bleeding has received approval from Canadian regulators. ZymoGenetics’ partner, Bayer AG, received clearance to start marketing recombinant thrombin (Recothrom), in Canada. ZymoGenetics, which first received approval of the drug in the U.S. in January 2008, will receive a $3.5 million payment in connection with the milestone.